Skip to main content

Some Lots of Tydemy Birth Control Pills Recalled Due to 'Reduced Effectiveness'

Medically reviewed by Drugs.com.

By Cara Murez HealthDay Reporter

WEDNESDAY, Aug. 2, 2023 -- Certain lots of the prescription birth control pill Tydemy may be less effective than expected, potentially resulting in an unintended pregnancy, because the pills do not contain enough of an active ingredient.

The U.S. Food and Drug Administration warned consumers about the issue Tuesday following a company announcement about the issue on July 29.

Two lots of Tydemy (drospirenone/ethinyl estradiol/levomefolate calcium) made by Lupin Pharmaceuticals do not contain the correct level of ascorbic acid, the FDA noted.

Lots L200183 and L201560, in 28-dose blister packs, were distributed throughout the United States between June 3, 2022, and May 31, 2023.

"To date, Lupin has received no reports of adverse events related to either recalled batches," the company noted. "Regardless, Lupin is recalling these two batches because if there were a significant reduction in the amount of inactive content (ascorbic acid), this could potentially impact the effectiveness of the product which could potentially result in unexpected pregnancy."

Patients should continue taking their medication, the FDA said, but they should also immediately contact their health care provider for advice about an alternative method of birth control.

The company had previously voluntarily recalled the two lots of Tydemy at the wholesale level.

"Consumers, wholesalers, distributors, and retailers with questions regarding this recall should contact Inmar Rx Solutions, Inc. at (866) 480-8206 Monday – Friday 9:00 a.m. to 5:00 p.m. EST," Lupin instructed in its statement. "For reimbursement, please have the recalled lots returned to Inmar Rx Solutions, Inc.; the lot number can be found on the side of the carton."

The FDA also encouraged health care providers and patients to report any adverse events or quality problems with this or other medications to the agency’s MedWatch Adverse Event Reporting program.

Sources

  • U.S. Food and Drug Administration, Aug. 1, 2023

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted August 2023

Read this next

Not 'Out of Your League': Folks Tend to Marry People as Attractive as They Are

MONDAY, July 1, 2024 -- People largely date and marry people in their own “league,” as far as beauty is concerned, a new review finds. Men and women are fairly...

States With Abortion Bans Also Saw Declines in Birth Control Post-Dobbs

WEDNESDAY, June 26, 2024 -- Post-Dobbs bans and restrictions on abortion are having a spillover effect in reducing the use of birth control and emergency contraception in those...

Texas' 2021 Abortion Ban Tied to Rise in Infant Deaths

MONDAY, June 24, 2024 -- Following state legislation passed in 2021 that essentially banned abortion in Texas, the rate of infant deaths rose by almost 13%, compared to a much...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.